Baylor Charles A. Sammons Cancer Center

Baylor Scott & White Health

Dallas, TX

Sorting 3 by

Accepting patients

APG-115

A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients With Relapse/Refractory AML, CMML or MDS
  • MDM2 Inhibitor
  • Phase 1/2

Accepting patients

TCR Engineered Donor T-Cells

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
  • T Cell (Allogeneic)
  • Phase 1
  • Has results

Accepting patients

LIMBER

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
  • BET Inhibitor
  • JAK1 Inhibitor
  • JAK2 Inhibitor
  • Phase 1